Should I buy or sell Akoya Biosciences stock right now?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Akoya Biosciences in the last year. There are currently 1 hold rating and 6 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" AKYA shares. View AKYA analyst ratings or view top-rated stocks .

What is Akoya Biosciences' stock price target for 2024?

7 equities research analysts have issued 12-month price objectives for Akoya Biosciences' shares. Their AKYA share price targets range from $7.50 to $11.00. On average, they anticipate the company's stock price to reach $9.07 in the next twelve months. This suggests a possible upside of 127.9% from the stock's current price. View analysts price targets for AKYA or view top-rated stocks among Wall Street analysts .

How have AKYA shares performed in 2024?

Akoya Biosciences' stock was trading at $4.88 on January 1st, 2024. Since then, AKYA stock has decreased by 18.4% and is now trading at $3.98. View the best growth stocks for 2024 here .

Are investors shorting Akoya Biosciences?

Akoya Biosciences saw a decrease in short interest in March. As of March 31st, there was short interest totaling 988,400 shares, a decrease of 5.9% from the March 15th total of 1,050,000 shares. Based on an average daily trading volume, of 203,800 shares, the short-interest ratio is currently 4.8 days. Currently, 4.7% of the company's shares are sold short. View Akoya Biosciences' Short Interest .

When is Akoya Biosciences' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, May 13th 2024. View our AKYA earnings forecast .

How were Akoya Biosciences' earnings last quarter?

Akoya Biosciences, Inc. (NASDAQ:AKYA) issued its quarterly earnings data on Monday, March, 4th. The company reported ($0.22) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.27) by $0.05. The company earned $26.49 million during the quarter, compared to analysts' expectations of $26.12 million. Akoya Biosciences had a negative net margin of 65.53% and a negative trailing twelve-month return on equity of 110.24%. During the same period in the prior year, the business earned ($0.50) EPS.

What guidance has Akoya Biosciences issued on next quarter's earnings?

Akoya Biosciences issued an update on its FY 2024 earnings guidance on Monday, March, 4th. The company provided EPS guidance of for the period. The company issued revenue guidance of $114.0 million-$118.0 million, compared to the consensus revenue estimate of $117.4 million.

When did Akoya Biosciences IPO?

Akoya Biosciences (AKYA) raised $125 million in an initial public offering (IPO) on Friday, April 16th 2021. The company issued 6,600,000 shares at a price of $18.00-$20.00 per share. J.P. Morgan, Morgan Stanley, Piper Sandler and Canaccord Genuity acted as the underwriters for the IPO.

How do I buy shares of Akoya Biosciences?

Shares of AKYA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:AKYA

Akoya Biosciences (AKYA) Stock Price, News & Analysis

→ He Is Giving Away Bitcoin (From Crypto Swap Profits) (Ad)

Free AKYA Stock Alerts

$3.98

-0.03 (-0.75%)

(As of 05:11 PM ET)

Compare

Today's Range: $3.85
▼
$4.10
50-Day Range: $4.01
▼
$6.06
52-Week Range: $3.04
▼
$8.80

Volume: 310,081 shs
Average Volume: 199,709 shs
Market Capitalization: $195.58 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $9.07

Get Akoya Biosciences alerts:

Akoya Biosciences MarketRank™ Stock Analysis

Analyst Rating: Moderate Buy
2.86 Rating Score
Upside/Downside: 127.9% Upside
$9.07 Price Target
Short Interest: Healthy
4.65% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 1.16
Based on 7 Articles This Week
Insider Trading: Selling Shares
$74,325 Sold Last Quarter
Proj. Earnings Growth: Growing
From ($0.86) to ($0.50) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.10 out of 5 stars

Medical Sector

354th out of 930 stocks

Analytical Instruments Industry

13th out of 27 stocks

3.4

Analyst's Opinion

Consensus Rating
Akoya Biosciences has received a consensus rating of Moderate Buy. The company's average rating score is 2.86, and is based on 6 buy ratings, 1 hold rating, and no sell ratings.
Amount of Analyst Coverage
Akoya Biosciences has only been the subject of 3 research reports in the past 90 days.

4.0

Short Interest

Percentage of Shares Shorted
4.65% of the float of Akoya Biosciences has been sold short.
Short Interest Ratio / Days to Cover
Akoya Biosciences has a short interest ratio ("days to cover") of 4.8.
Change versus previous month
Short interest in Akoya Biosciences has recently decreased by 5.87%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
Akoya Biosciences does not currently pay a dividend.
Dividend Growth
Akoya Biosciences does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for AKYA.

3.4

News and Social Media Coverage

News Sentiment
Akoya Biosciences has a news sentiment score of 1.16. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.66 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 7 news articles for Akoya Biosciences this week, compared to 2 articles on an average week.
Search Interest
2 people have searched for AKYA on MarketBeat in the last 30 days.

2.5

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Akoya Biosciences insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $74,325.00 in company stock.
Percentage Held by Insiders
Only 8.50% of the stock of Akoya Biosciences is held by insiders.
Percentage Held by Institutions
79.42% of the stock of Akoya Biosciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Akoya Biosciences are expected to grow in the coming year, from ($0.86) to ($0.50) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Akoya Biosciences is -2.69, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Akoya Biosciences is -2.69, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Akoya Biosciences has a P/B Ratio of 3.62. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad Insiders Exposed

This consistently signaled gains of 453%... 610%... and even 1036%...

It doesn’t happen often, but occasionally, something completely unique comes across my radar. In this case, I’m talking about legal “Insider Trading”. Traders who have consistently signaled 453% … 610% .. and even 1036%... gains. And until now they have been doing it completely under the radar. In an upcoming interview I am revealing the strategy behind this gold-mine and how you can piggy back their every trade.

About Akoya Biosciences Stock (NASDAQ:AKYA)

Akoya Biosciences, Inc., a life sciences technology company, provides spatial biology solutions focused on transforming discovery and clinical research in North America, the Asia Pacific, Europe, the Middle East, and Africa. The company offers PhenoCycler instrument, a compact bench-top fluidics system that integrates with a companion microscope to automate image acquisition; and PhenoImager platform that enables researchers to visualize, analyze, quantify, and phenotype cells in situ, in fresh frozen or FFPE tissue sections, and tissue microarrays utilizing an automated and high-throughput workflow. It also provides PhenoCycler and PhenoImager reagents; and biopharma services. In addition, the company offers analysis software partnerships ecosystem; inForm Tissue, an automated image analysis software package for accurately visualizing and quantifying biomarkers in tissue sections; Phenoptr, which provides functions that consolidate and analyze output tables created by inForm software; and phenoptrReports, a software that generates shareable reports and visualizations based on the phenoptr output in an intuitive front-end GUI. The company was incorporated in 2015 and is headquartered in Marlborough, Massachusetts.

AKYA Stock Price History

30 days | 90 days | 365 days | Advanced Chart

AKYA Stock News Headlines

March 23, 2024 | insidertrades.com

Akoya Biosciences, Inc. (NASDAQ:AKYA) CEO Brian Mckelligon Sells 7,500 Shares

April 15, 2024 | americanbankingnews.com

Akoya Biosciences, Inc. to Post Q2 2024 Earnings of ($0.26) Per Share, Capital One Financial Forecasts (NASDAQ:AKYA)

April 16, 2024 | Priority Gold (Ad)

Red Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!

Get your free information kit NOW, before it’s too late. Inside you’ll get the 3 secret strategies you can put in place starting today, so “they” don’t get your money tomorrow.

April 9, 2024 | markets.businessinsider.com

Piper Sandler Keeps Their Buy Rating on Akoya Biosciences (AKYA)

April 5, 2024 | globenewswire.com

Akoya Biosciences Showcases Spatial Biology 2.0 Solutions at AACR Annual Meeting with Case Studies Demonstrating Unprecedented Speed and Scale

March 16, 2024 | uk.investing.com

Akoya Biosciences CEO sells $37k worth of shares

March 9, 2024 | uk.investing.com

Akoya Biosciences Inc (AKYA)

March 6, 2024 | seekingalpha.com

Akoya Biosciences, Inc. (AKYA) Q4 2023 Earnings Call Transcript

April 16, 2024 | Priority Gold (Ad)

Red Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!

Get your free information kit NOW, before it’s too late. Inside you’ll get the 3 secret strategies you can put in place starting today, so “they” don’t get your money tomorrow.

March 6, 2024 | markets.businessinsider.com

Massaro Issues Buy Rating for Akoya Biosciences Amid Strong Financial Performance and Market Growth Potential

March 5, 2024 | finance.yahoo.com

Akoya Biosciences, Inc. (NASDAQ:AKYA) Q4 2023 Earnings Call Transcript

March 5, 2024 | finanznachrichten.de

Akoya Biosciences, Inc.: Akoya Reports Record Revenue in the Fourth Quarter of 2023 and Provides Full Year 2024 Financial Outlook

March 5, 2024 | finance.yahoo.com

Q4 2023 Akoya Biosciences Inc Earnings Call

March 4, 2024 | investorplace.com

AKYA Stock Earnings: Akoya Biosciences Beats EPS, Beats Revenue for Q4 2023

March 4, 2024 | benzinga.com

Recap: Akoya Biosciences Q4 Earnings

March 4, 2024 | msn.com

Akoya Biosciences GAAP EPS of -$0.22 beats by $0.06, revenue of $26.5M beats by $0.39M

March 4, 2024 | finance.yahoo.com

Akoya Biosciences Inc (AKYA) Reports Record Q4 Revenue and Sets Positive 2024 Outlook

March 4, 2024 | globenewswire.com

Akoya Reports Record Revenue in the Fourth Quarter of 2023 and Provides Full Year 2024 Financial Outlook

March 3, 2024 | markets.businessinsider.com

Akoya Biosciences earnings: here's what to expect

March 1, 2024 | benzinga.com

Earnings Outlook For Akoya Biosciences

February 24, 2024 | finance.yahoo.com

Akoya Biosciences Insiders Placed Bullish Bets Worth US$2.11m

February 22, 2024 | benzinga.com

Akoya Biosciences Stock (NASDAQ:AKYA) Insider Trades

February 16, 2024 | finance.yahoo.com

RNA Mar 2024 12.500 put

February 8, 2024 | finance.yahoo.com

Akoya to Report Fourth Quarter and Full Year 2023 Financial Results on March 4th, 2024 and Participate at an Upcoming Investor Conference

February 7, 2024 | finance.yahoo.com

Strength Seen in Akoya (AKYA): Can Its 7.4% Jump Turn into More Strength?

January 31, 2024 | benzinga.com

Akoya Biosciences Stock (NASDAQ:AKYA) Dividends: History, Yield and Dates

January 31, 2024 | finance.yahoo.com

Bristol Myers' (BMY) sBLAs for Breyanzi Get FDA Priority Tag

See More Headlines

Receive AKYA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Akoya Biosciences and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 3/04/2024
Today: 4/16/2024
Next Earnings (Estimated): 5/13/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Analytical instruments
Sub-Industry: N/A
Current Symbol: NASDAQ:AKYA
CUSIP: N/A
CIK: 1711933
Web: www.akoyabio.com
Phone: 855-896-8401
Fax: N/A
Employees: 330
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $9.07
High Stock Price Target: $11.00
Low Stock Price Target: $7.50
Potential Upside/Downside: +127.9%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.86
Research Coverage: 7 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($1.48)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-63,320,000.00
Net Margins: -65.53%
Pretax Margin: -65.49%
Return on Equity: -110.24%
Return on Assets: -36.14%

Debt

Debt-to-Equity Ratio: 1.41
Current Ratio: 3.45
Quick Ratio: 2.94

Sales & Book Value

Annual Sales: $96.63 million
Price / Sales: 2.02
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $1.10 per share
Price / Book: 3.62

Miscellaneous

Outstanding Shares: 49,140,000
Free Float: 44,964,000
Market Cap: $195.58 million
Optionable: Optionable
Beta: 1.48

A Guide To High-Short-Interest Stocks

MarketBeat's analysts have just released their top five short plays for April 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

Mr. Brian McKelligon (Age 55)
President, CEO & Director
Comp: $1.15M
Mr. John Frederick Ek (Age 48)
CFO, Principal Financial Officer & Principal Accounting Officer
Dr. Frederic G. Pla Ph.D. (Age 65)
Chief Operating Officer
Comp: $445.27k
Priyam Shah
Senior Director of Business Development & Investor Relations Strategy
Ms. Jennifer Kamocsay (Age 53)
General Counsel
Dr. Niro Ramachandran Ph.D. (Age 49)
Chief Business Officer
Comp: $298.18k
Dr. Pascal Bamford Ph.D.
Senior Vice President, Research & Development and Laboratory Operations
Mr. Rob C. Hart CFA
J.D., Secretary

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

AKYA Stock Analysis - Frequently Asked Questions

Should I buy or sell Akoya Biosciences stock right now?: 7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Akoya Biosciences in the last year. There are currently 1 hold rating and 6 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" AKYA shares.
View AKYA analyst ratings or view top-rated stocks.
What is Akoya Biosciences' stock price target for 2024?: 7 equities research analysts have issued 12-month price objectives for Akoya Biosciences' shares. Their AKYA share price targets range from $7.50 to $11.00. On average, they anticipate the company's stock price to reach $9.07 in the next twelve months. This suggests a possible upside of 127.9% from the stock's current price.
View analysts price targets for AKYA or view top-rated stocks among Wall Street analysts.
How have AKYA shares performed in 2024?: Akoya Biosciences' stock was trading at $4.88 on January 1st, 2024. Since then, AKYA stock has decreased by 18.4% and is now trading at $3.98.
View the best growth stocks for 2024 here.
Are investors shorting Akoya Biosciences?: Akoya Biosciences saw a decrease in short interest in March. As of March 31st, there was short interest totaling 988,400 shares, a decrease of 5.9% from the March 15th total of 1,050,000 shares. Based on an average daily trading volume, of 203,800 shares, the short-interest ratio is currently 4.8 days. Currently, 4.7% of the company's shares are sold short.
View Akoya Biosciences' Short Interest.
When is Akoya Biosciences' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Monday, May 13th 2024.
View our AKYA earnings forecast.

How were Akoya Biosciences' earnings last quarter?: Akoya Biosciences, Inc. (NASDAQ:AKYA) issued its quarterly earnings data on Monday, March, 4th. The company reported ($0.22) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.27) by $0.05. The company earned $26.49 million during the quarter, compared to analysts' expectations of $26.12 million. Akoya Biosciences had a negative net margin of 65.53% and a negative trailing twelve-month return on equity of 110.24%. During the same period in the prior year, the business earned ($0.50) EPS.
What guidance has Akoya Biosciences issued on next quarter's earnings?: Akoya Biosciences issued an update on its FY 2024 earnings guidance on Monday, March, 4th. The company provided EPS guidance of for the period. The company issued revenue guidance of $114.0 million-$118.0 million, compared to the consensus revenue estimate of $117.4 million.
When did Akoya Biosciences IPO?: Akoya Biosciences (AKYA) raised $125 million in an initial public offering (IPO) on Friday, April 16th 2021. The company issued 6,600,000 shares at a price of $18.00-$20.00 per share. J.P. Morgan, Morgan Stanley, Piper Sandler and Canaccord Genuity acted as the underwriters for the IPO.
How do I buy shares of Akoya Biosciences?: Shares of AKYA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:AKYA) was last updated on 4/16/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial